Mammalian Target of Rapamycin (mTOR) Pathways in Neurological Diseases

Biomedical Journal - Netherlands
doi 10.4103/2319-4170.110365
Full Text
Abstract

Available in full text

Categories
Medicine
Date
Authors
Publisher

Elsevier BV

Related search

Mammalian Target of Rapamycin (mTOR; FRAP; RAFT1)

Science-Business eXchange
2010English

Mammalian Target of Rapamycin (mTOR) Inhibition in Advanced Bronchial Carcinoids

European Oncology and Haematology
OncologyHematology
2015English

Mammalian Target of Rapamycin (mTOR) as a Potential Therapeutic Target in Pathological Ocular Angiogenesis

Biological and Pharmaceutical Bulletin
MedicinePharmacologyPharmaceutical Science
2017English

Mammalian Target of Rapamycin: A Target for (Lung) Diseases and Aging

Annals of the American Thoracic Society
PulmonaryRespiratory Medicine
2016English

New Targets for Therapy in Breast Cancer: Mammalian Target of Rapamycin (mTOR) Antagonists

Breast Cancer Research
Cancer ResearchOncology
2004English

Ku-0063794 Is a Specific Inhibitor of the Mammalian Target of Rapamycin (mTOR)

Biochemical Journal
BiochemistryCell BiologyMolecular Biology
2009English

Activation of the Mammalian Target of Rapamycin (mTOR) Is Essential for Oligodendrocyte Differentiation

Journal of Neuroscience
Neuroscience
2009English

Mammalian Target of Rapamycin (mTOR) Inhibition: Potential for Antiseizure, Antiepileptogenic, and Epileptostatic Therapy

Current Neurology and Neuroscience Reports
NeuroscienceNeurology
2012English

Mammalian Target of Rapamycin (mTOR; FRAP; RAFT1); Transforming Growth Factor-Β1 (TGFB1; TGFβ1)

Science-Business eXchange
2010English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy